Floatz logo

PERFLUTREN

Interstitial Lung Disease

Thunder Bay Regional Health Research InstituteSmall moleculeEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

18 Active assets in the Interstitial Lung Disease cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
National Institute for Tuberculosis and Lung Diseases, Poland
Phase 4BB
TREPROSTINIL PHOSPHATE
United Therapeutics
Phase 3BB
Cyclophosphamide
Intergroupe Francophone de Cancerologie Thoracique
Phase 2/3B
Sildenafil
University of California, Los Angeles
Phase 4B
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Royal Brompton & Harefield NHS Foundation Trust
Phase 2/3B

View all 35 →

Same molecule, other indications

PERFLUTREN is also rated in:

Recurrent Renal Cell CarcinomaDormant
B
Indicative ·
60 / 100
View asset →
asthmaDormant
B
Indicative ·
60 / 100
View asset →
Kidney CancerDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →